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Abstract
Background: There are few validated tools to measure stigma, particularly among children living with HIV and their families.
Methods: This study was nested within a larger study that followed 240 child–caregiver dyads (children aged 10-15 years) at 8
clinics in western Kenya. The stigma instrument was administered to all child–caregiver dyads at 2 time points 6 months apart. The
primary end point was to construct validity assessed by comparison to criterion constructs using generalized estimating equation
models. Results:Mean age of child participants was 12.3 years and 52% were female. Generally, caregivers reported experiencing
higher levels of HIV stigma compared to their children. Children (9%) and caregivers (14%) reported that HIV stigma made them
feel stressed, anxious, and depressed. Child and caregiver stigma items showed high construct validity by emotional and behavioral
outcomes. Conclusions: The stigma instrument showed high validity when compared to emotional and behavioral outcomes.
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Introduction
HIV-related stigma is an important barrier to all aspects of HIV
prevention and treatment, including delayed HIV testing and
enrollment in care,1–3 increased risk of not being retained in
care,4–6 nonadherence to antiretroviral therapy (ART),7–10 and
higher likelihood of nondisclosure to partners.11,12 The nega-
tive impact of HIV stigma on psychosocial health, such as
depression, anxiety, and decreased quality of life (QoL), has
also been noted.13–16 Unfortunately, the literature on HIV
stigma has been heavily skewed toward adults living with HIV
and has not adequately considered the impact of stigma on
children and adolescents living with HIV, most of whom reside
in sub-Saharan Africa.17
An estimated 1.8 million children younger than 15 years are
living with HIV, with less than half accessing ART.18 Children
living with HIV may be at substantial risk of HIV stigma and its
deleterious effects on HIV treatment and psychosocial health in
ways both similar and distinct from adults. For example,
perinatally infected children are at higher risk for stunted
growth and delayed bodily development, and these differences
in appearance may be a source of anxiety and internalized
stigma or increase risks for social isolation and discrimination.
Studies suggest that HIV stigma encountered from peers at
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school in the form of taunting, gossiping, or bullying, either
because of the child’s own status or the status of a family
member, are formative experiences for HIV-infected and
affected youth19–22 and may lead to problems in school atten-
dance or accessing peer support networks.23–25 Moreover, chil-
dren may be affected by HIV stigma experienced at the
caregiver level, which has been shown to negatively impact
HIV-infected children,26–28 including caregivers delaying giv-
ing children medicines or taking them to clinical care.29–31
Generally, HIV stigma has been hypothesized to exacerbate
poverty, malnutrition, and access to services for HIV-affected
families.32–34
As more children access treatment, survive into adoles-
cence, and transition into adult care settings, they must learn
about their HIV status. Parents and caregivers of children with
HIV often report that disclosure to children will improve ART
adherence,35–44 increase the child’s long-term engagement
in care,35,38–42,44–46 and equip the child to protect himself or
herself and others fromHIV.39,43,47 On the other hand, the poten-
tial negative impacts of HIV stigma weigh heavily in decisions
about disclosure. Studies frequently cite parents’ and caregivers’
fears that the child will subsequently disclose his or her HIV
status to others,38–41,44,46,48–50 leading to potential stigma and
social isolation for the child as well as the family.38,40,41,44,45,49
A major barrier to investigating the prevalence and impacts
of HIV stigma among children living with HIV and their fam-
ilies, as well as evaluating interventions to combat stigma, is
the lack of reliable and valid stigma measures, particularly in
resource-limited settings.51–53 Several authors of this paper
(blinded) previously undertook a systematic review of mea-
sures of HIV stigma among HIV-infected and affected
children.54 Among 27 articles describing quantitative HIV
stigma measures for HIV-infected and affected youth younger
than 18 years, only a handful explicitly evaluated the validity of
stigma measures using rigorous methods to ensure content
validity, internal consistency, and construct validity, with most
studies modifying existing measures such as the HIV Stigma
Scale developed among adults in the United States. In this
article, we report the results of the SAFI (Stigma in AIDS
Family Inventory) validation study that aimed to systematically
evaluate a culturally adapted, developmentally appropriate
measure to assess HIV stigma experienced by children living
with HIV and their caregivers in western Kenya.
Methods
Study Design
We conducted a multiphased validation study to develop and
test a reliable, valid instrument to measure HIV stigma among
children living with HIV and their families. In the first phase,
we constructed a questionnaire for children and their care-
givers. A potential set of questionnaire items were identified
through a systematic review of existing questionnaires and
other methods used for pediatric HIV stigma measurement.54
We utilized a conceptual framework that assumes people living
with HIV (or caring for those living with HIV) may experience
4 types of HIV stigma that operate in subtle but in distinctive
ways. Perceived and enacted stigma are characterized by the
fear that HIV stigma and discrimination may occur and the
belief that it has occurred, while internalized stigma captures
negative beliefs among oneself because of their HIV
status.55,56 A fourth type of stigma, courtesy stigma, describes
stigma and discrimination directed at an individual who is
associated with or attending to someone who is living with
HIV (but not necessarily infected themselves), which has
important consequences for families caring for infected chil-
dren.57 We incorporated these various dimensions of stigma
into the stigma questionnaire.
Adaptation of stigma questionnaire items in the literature
and the conceptual framework to the local setting and popula-
tion were informed by focus groups with children living with
HIV and caregivers of HIV-infected children (results published
elsewhere), as well as cognitive interviews with children and
caregivers to test and maximize face validity of items. The final
set of stigma questionnaire items was translated from English
to Kiswahili by a trained translator and then back-translated
into English, repeating this process until items were consistent.
Following recommendations for cross-cultural test adapta-
tion,58 a team of multicultural and multilingual experts
reviewed the translations and assessed items for cultural sensi-
tivity and intercultural communication. This team has exten-
sive qualitative research methods and instrument validation
and cross-cultural adaptation expertise in this setting, particu-
larly related to pediatric adherence to treatment and disclosure
of HIV status in which issues of stigma are prominent.31,44,59–64
What Do We Already Know About This Topic?
HIV stigma is a major barrier to all aspects of HIV testing
and treatment, but there are few validated tools to measure
stigma among children living with HIV.
How Does Your Research Contribute to the
Field?
Using a mixed-methods approach, we developed and
tested a grounded stigma instrument among children liv-
ing with HIV in western Kenya, which showed good con-
struct validity with relevant emotional and behavioral
outcomes.
What Are Your Research’s Implications Toward
Theory, Practice, or Policy?
Our research demonstrates that it is possible to develop a
simple, low-cost questionnaire to identify children experi-
encing HIV-related stigma in a clinical setting who can be
targeted for additional intervention or services.
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The resultant questionnaire, known as the SAFI Stigma
questionnaire, asks a series of questions regarding the stigma
and discrimination that an individual experiences because of
his/her own or someone in their families’ HIV status. Partici-
pants were instructed to respond to an experience as having
“never happened” or “ever happened.” If “ever happened” was
selected, the participant was then prompted to describe the time
frame in which the experience happened, categorized as either
in the “past 6 months” or “longer than 6 months ago.” Many of
the question prompts are led by the statement, “Because I have
HIV or someone else in my family has HIV . . . ”
In the second phase, which are reported here, we tested the
reliability and validity of the HIV stigma questionnaire items
(child and/or caregiver stigma questionnaires provided on
request). Reliability and validity testing was nested within a
cluster, randomized, prospective cohort study to evaluate a dis-
closure counseling intervention. The study followed 240 fami-
lies with HIV-infected children aged 10 to 15 years for 2 years at
8 clinics (*35 children per clinic), who are part of the Academic
Model Providing Access to Healthcare (AMPATH) in western
Kenya, one of the largest HIV care providers in sub-Saharan
Africa.65,66 Informed consent was required from all of the child
participants’ parents or guardians, and assent was also required
from all child participants. Study assessments were conducted at
baseline and every 6 months thereafter, which included clinical
characteristics (WHO disease stage, CD4 counts, and viral load)
and various questionnaires administered by research assistants
assessing disclosure status, adherence to treatment, behavioral
and mental health, and QoL. Child participants were also issued
Medication Event Monitoring Systems (MEMS® Cap, Wes-
tRock, Atlanta, USA) caps for electronic dose monitoring. Base-
line characteristics of this cohort and study methods, including
the various assessments and how they were interpreted, are pub-
lished elsewhere.67 The stigma questionnaire was administered
(in English or Kiswahili, depending on participant preference) to
all children and their caregivers at the final 2 routine study
evaluations (month 18 and 24) alongside the other assessments.
Due to the fact that the stigma questionnaire specifically refer-
ences HIV, only children who were disclosed and knew their
HIV status were administered the stigma questionnaire (all care-
givers were administered the questionnaire). At month 18 and
24, 126 and 155 children were administered the stigma ques-
tionnaire, respectively. Data were collected from October 2014
to June 2015.
Ethical Statement
The study was approved by the institutional review board of
Indiana University School of Medicine (Protocol #1206009036)
in Indianapolis, Indiana, and the Moi University/Moi Teaching
and Referral Hospital Institutional Research and Ethics
Committee (Approval #000872) in Eldoret, Kenya. All study
participants aged 18 years and older provided informed consent
prior to enrollment. For children younger than 18 years, we
obtained assent as well as informed consent from their guardian
according to local laws and guidelines. Research participants
were provided with a small stipend (about US$3) per study
assessment to compensate them for their travel and time. To
reduce the risk of accidental disclosure ofHIV status to children,
research assistants underwent additional training before
consenting and assessing study participants, which included
modules on disclosure assessment protocols, confidentiality,
and privacy. Additionally, research assistants were trained to
refer any participants whom they deemed to be demonstrating
significant psychiatric distress. A specific mental health study
referral form was created to document and refer participants for
mental health services.
Analysis
Descriptive statistics and item analysis of the participants’
responses to stigma measurement items were conducted,
including item response distribution, item discrimination
indices, and item-scale correlation. Test–retest reliability was
assessed for individual stigma items at the 2 time points for
stigma items administered to children and separately for stigma
items administered to caregivers. We also examined the agree-
ment between child and caregiver responses to individual
stigma items that were sufficiently similar (a total of 8 items),
which was assessed using k statistics. The primary end point of
the validation study was construct validity, which was assessed
by comparison to primary criterion constructs using general-
ized estimating equation (GEE) models. These GEE models
allowed for the modeling of repeated measures across visits,
gave the ability to accurately model the covariance structure to
ensure the best fit, and allowed for the use of distributions
within the exponential family, to model nonlinear data. Primary
criterion constructs were adherence to treatment, QoL, beha-
vioral health, depression, and clinical characteristics. Adher-
ence was assessed using a previously validated questionnaire in
this setting that asks about missed and late doses as well as
barriers to adherence.59,60 In addition, participants were issued
electronic dose monitors (MEMS) that recorded a time and date
stamp each time the bottle was opened. Quality of life was
assessed using the multidomain Pediatric AIDS Clinical Trials
Group General Health Assessment for Children (GHAC) QoL
questionnaire developed by the Pediatric AIDS Clinical Trial
Group. The GHAC was constructed through previously vali-
dated measures with good internal consistency, reliability, and
validity. The modular, age-specific GHAC instrument for chil-
dren measured the QoL on the following 5 domains: general
health, physical functioning, symptoms, psychological well-
being, and social and role functioning. Each domain of the
GHAC is scored separately on a Likert scale, with scaled scores
ranging from 0 to 100, with higher scores indicating better
QoL.68–70 Behavioral health was assessed using the 25-item
Strengths and Difficulties Questionnaire (SDQ)–Youth Ver-
sion,71,72 which consists of 5 scales that measure difficulties
in 5 psychological domains: emotional symptoms, conduct
problems, hyperactive-inattention, peer relationship, and pro-
social behavior. Participants are asked to rank their behaviors
as “not true,” “somewhat true,” or “certainly true.” Depression
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was assessed using the Patient Health Questionnaire–9-item
(PHQ-9) depression instrument,73 a 9-item module adapted
from the full PHQ assessment and provides diagnosis of prob-
able depression and assesses severity of symptoms. Participants
are asked to report how often they have experienced depressive
symptoms over the last 2 weeks, on a scale of 0 (not at all) to 3
(nearly every day). The PHQ-9 has demonstrated high internal
reliability. Patient responses to the GHAC,69,74,75 SDQ,71,72
and PHQ-976 were scored and transformed consistent with the
published literature. Linear (for continuous outcome variables)
and logistic (for dichotomized variables) regression models
were used for validating stigma items against criterion con-
structs, while accounting for key demographic variables.
Demographic and clinical characteristics were extracted from
the participants’ medical chart using a standardized clinical
data extraction tool.
Results
Participants’ Characteristics
At study baseline, mean age of child participants was 12.3 years
and 147 were female (52%), with the majority of caregiver
participants being the biological mother of the child (54%), as
well as a number of aunts/uncles (19%), biological fathers
(17%), and grandparents (11%; Table 1). About half of children
were total orphans (ie, both their mother and father were
deceased) and a fifth has a siblingwhowas also livingwithHIV.
Adherence monitoring using MEMS revealed only 28% of
children were able to sustain >90% of doses taken over
the follow-up period, with median adherence of 70% of
disease taken.
Responses to the Stigma Questionnaire
Child and caregiver participants’ responses to stigma items are
provided in Table 2. A small proportion of children (ie, less than
10%) responded that they had lost friends due to their HIV
status, had been bullied or insulted, experienced HIV-related
discrimination, and had lost social support. More children,
although still a minority, reported that their HIV status had made
them feel stressed or anxious (9% at month 24) or depressed or
sad (9% at month 24). Almost half of the children (45%)
reported that it was important to keep their HIV status a secret
(45%), but only 11% reported that they delayed taking their HIV
medications so others would not see them. Caregivers reported
slightly higher levels of stress or anxiety (13% at month 24) and
depression or sadness (14% at month 24) due to their child’s
HIV status. Moreover, caregivers were more likely to report
other forms of stigma and discrimination that they experienced.
For example, while 11% of caregivers reported being called
names or bullied due to the child’s HIV status, only 3% of
children reported these experiences, and 10% of caregivers
reported experiencing discrimination in the neighborhood com-
pared with only 2% of children. Caregivers were also much more
likely to report thinking that people in the community think HIV
is a dirty or immoral disease, with 21% reporting a few people
think that and 19% reporting most people think that.
Reliability and Construct Validity
Test–retest reliability was high; responses by both children and
caregivers on individual stigma items were highly consistent
frommonth 18 to month 24 (agreement was >90% for the major-
ity of stigma items). Child and caregiver stigma items showed
high construct validity, with the SDQ and caregiver stigma items
showed high construct validity with the GHAC General Health
(Table 3). Several caregiver stigma items also showed construct
validity with MEMS adherence and viral load. No child or care-
giver stigma items were significantly associated with child- or
caregiver-reported adherence using the CAMPAdherence Ques-
tionnaire, depression using the PHQ-9 questionnaire, or any
GHAC domains outside of General Health (ie, no items corre-
lated with physical functioning, psychological functioning,
social and role, HIV, and health care).
On the child questionnaire, stigma items that showed high
construct validity with the SDQ included experiencing dis-
crimination at home due to HIV, losing social support, feeling
stressed/anxious due to HIV stigma, feeling depressed/sad
due to HIV stigma, and hopes for the future changing in a
negative way due to HIV. Similar but not identical stigma
items on the caregiver questionnaire showed high construct
Table 1. Participants’ Characteristics.
Characteristics N
Mean + SD or
Median (IQR) or n (%)
Age (years) 285 12.31+ 1.50
Male 285 147 (51.6%)
CD4 (cells per mm3) 271 732.84+ 504.26
CD4 percent 259 26.45+ 10.38
WHO stage 282
1 90 (31.9%)
2 90 (31.9%)
3 92 (32.6%)
4 10 (3.6%)
Orphan status 285
Both parents deceased 141 (49.5%)
Mother deceased 89 (31.2%)
Father deceased 90 (31.6%)
Sibling has HIV 265 52 (19.6%)
Caregiver at assessment 285
Mother 155 (54.4%)
Father 48 (16.8%)
Sibling 14 (4.9%)
Grandparent 31 (10.9%)
Aunt/uncle 55 (19.3%)
Children’s home 5 (1.8%)
Others 8 (2.8%)
Attends school 279 275 (98.6%)
MEMS % doses taken 270 70.54 (46.4)
MEMS adherent (>90%) 270 76 (28.2%)
Abbreviations: IQR, interquartile region; MEMS, Medication Event Monitoring
Systems; SD, standard deviation.
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validity with the SDQ, including being called names/insulted
due to the child’s HIV status, losing financial support/work
due to the child’s HIV status, feeling depressed/sad due to
HIV stigma, and that the child’s future hopes had changed
in a negative way. All child and caregiver stigma items
showed high construct validity in the same “direction”—that
Table 2. Responses to Stigma Items.
Stigma Items
Frequency Responding That Item “Ever Happened” (and %)
Month 18 Month 24
Child stigma items N ¼ 126 N ¼ 155
Q1. Lost friends due to HIV status 8 (6.4%) 3 (1.9%)
Q2. Called names/bullied/insulted due to HIV 9 (7.1%) 5 (3.3%)
Q3a. Experienced discrimination at home due to HIV 6 (4.8%) 6 (3.9%)
Q3b. Experienced discrimination in neighborhood due to HIV 8 (6.4%) 3 (2.0%)
Q3c. Experienced discrimination at church due to HIV 0 (0%) 1 (0.7%)
Q3d. Experienced discrimination at clinic due to HIV 0 (0%) 0 (0%)
Q3e. Experienced discrimination at school due to HIV 7 (5.6%) 4 (2.6%)
Q3f. Experienced discrimination at another place due to HIV 1 (0.8%) 0 (0%)
Q4a. Lost financial support/work due to HIV 4 (3.2%) 1 (0.7%)
Q4b. Lost social support due to HIV 2 (1.6%) 0 (0%)
Q5a. HIV stigma has made me feel stressed/anxious 11 (8.7%) 14 (9.2%)
Q5b. HIV stigma has made me feel depressed/saddened 9 (7.1%) 14 (9.2%)
Q6. Choose not to play with others or go places due to HIV 4 (3.2%) 9 (5.9%)
Q7. Feel it is important to keep HIV status secret 72 (57.1%) 69 (45.1%)
Q8. Caregiver feels it is important to keep my HIV status secret 70 (56.5%) 65 (42.8%)
Q9. Future and hopes have changed in a negative way due to HIV 8 (6.4%) 8 (5.2%)
Q10. Delayed taking meds so others do not see 17 (13.5%) 17 (11.1%)
Q11. People in community think HIV is dirty/immoral/shameful
No one thinks 82 (66.1%) 117 (78.5%)
A few people think 31 (25.0%) 18 (12.1%)
Most people think 11 (8.9%) 14 (9.4%)
Caregiver stigma items N ¼ 254 N ¼ 251
Q1. Negatively judged due to child’s HIV 30 (11.9%) 25 (10.0%)
Q2. Isolated/avoided due to child’s HIV 23 (9.1%) 21 (8.4%)
Q3. Called names/insulted due to child’s HIV 31 (12.4%) 27 (10.8%)
Q4a. Experienced discrimination at home due to child’s HIV 19 (7.5%) 20 (8.0%)
Q4b. Experienced discrimination in neighborhood due to child’s HIV 23 (9.1%) 26 (10.4%)
Q4c. Experienced discrimination at church due to child’s HIV 4 (1.6%) 6 (2.4%)
Q4d. Experienced discrimination at clinic due to child’s HIV 1 (0.4%) 2 (0.8%)
Q4e. Experienced discrimination at work due to child’s HIV 5 (2.0%) 3 (1.2%)
Q4f. Experienced discrimination at another place due to child’s HIV 3 (1.2%) 3 (1.3%)
Q5a. Lost financial support/work due to child’s HIV 15 (5.9%) 11 (4.4%)
Q5b. Lost social support due to child’s HIV 17 (6.8%) 12 (4.8%)
Q6a. HIV stigma has made me feel stressed/anxious 31 (12.3%) 33 (13.2%)
Q6b. HIV stigma has made me feel depressed/saddened 34 (13.5%) 34 (13.6%)
Q7. Not allowed child to play with others or go places due to child’s HIV 10 (4.0%) 12 (4.8%)
Q8. People in community think HIV is dirty/immoral/shameful
No one thinks 143 (56.8%) 150 (60.5%)
A few people think 62 (24.6%) 52 (21.0%)
Most people think 47 (18.7%) 46 (18.5%)
Q9. Child is isolated/avoided due to HIV 17 (6.8%) 22 (8.8%)
Q10. Child has been called names/bullied/insulted 18 (7.1%) 23 (9.2%)
Q11a. Child has experienced discrimination at home 15 (5.9%) 17 (6.8%)
Q11b. Child has experienced discrimination in neighborhood 19 (7.5%) 15 (6.0%)
Q11c. Child has experienced discrimination at church 2 (0.8%) 4 (1.6%)
Q11d. Child has experienced discrimination at clinic 0 (0%) 2 (0.8%)
Q11e. Child has experienced discrimination at school 12 (4.8%) 8 (3.2%)
Q11f. Child has experienced discrimination at another place 0 (0%) 1 (0.4%)
Q12a. HIV discrimination affected child socially 11 (4.3%) 8 (3.2%)
Q12b. HIV discrimination affected child emotionally 13 (5.1%) 24 (9.6%)
Q12c. HIV discrimination affected child’s education 10 (4.0%) 14 (5.6%)
Q13. Child’s future and hopes changed in a negative way 13 (5.2%) 14 (5.6%)
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is, child and caregiver reports of stigma/discrimination or its
negative effects on the stigma questionnaire were associated
with poorer total difficulties scores on the SDQ (poorer emo-
tional and behavioral health). Five caregiver stigma items
showed high construct validity, with the GHAC General
Health domain in the same direction as the results above.
These items were related to feeling depressed/sad due to HIV
stigma (which also showed validity with the SDQ), the child
being isolated due to their HIV status, the child experiencing
discrimination at home or at school, and HIV discrimination
affecting the child’s education.
Agreement Between Child and Caregiver Responses
There were 8 items on the child and caregiver questionnaires that
asked about HIV stigma that the child had experienced with the
items being sufficiently similar to compare child and caregiver
responses. Agreement was fairly high (between 84% and 100%),
but not all k statistics were statistically significant (Table 4).
Overall, caregivers were slightly more likely to report that their
child had experienced stigma when compared to child self-
reports. For example, at month 18, only 3% of children reported
being called names or bullied due to their HIV status but 9% of
caregivers reported their child was called names or bullied.
Discussion
A minority but not insignificant proportion of children and
caregivers reported fearing or experiencing HIV stigma among
this cohort of families in western Kenya. Generally, caregivers
tended to report high levels of both child-level and caregiver-
level stigma. Our results support that the phenomenon of
courtesy stigma, whereby caregivers may fear or directly expe-
rience stigma due to the status of their child (rather than their
own status), is an important characteristic of HIV stigma in this
setting, which can affect child outcomes both clinically and
psychosocially.77 Up to 1 in 10 caregivers in our cohort
reported being negatively judged or isolated/avoided due to the
child’s HIV status. In their qualitative study of HIV-related
sigma in the United States, Bogart and colleagues referred to
this phenomenon as the “interconnectedness of stigma experi-
ences in families living with HIV.”78 Our study supports the
need for instruments to be attentive to the ways in which HIV
stigma can impact families caring for children living with HIV.
The lower levels of stigma reports from children versus their
caregivers deserve further investigation in this setting. Given
many of the children’s younger age—average age was 12
years—it is possible that many children, even though they
knew about their HIV status, were too young to recognize or
connect their feelings and experiences to HIV-related stigma. It
is also possible that because only children who were disclosed
to were administered the questionnaire but all caregivers
responded, the children who were yet to be disclosed to were
more at risk of HIV stigma. Studies report a close association
between caregivers’ fears of HIV stigma and nondisclosure to
children,62 which we also found in our own focus groups with
caregivers in this setting. Finally, children in this setting may
be reluctant to report their own internal or external experiences
of HIV stigma; about half of children reported that they felt it
was important to keep their HIV status a secret. This may
extend to keeping their own feelings and experiences related
to HIV stigma private. Among adolescents in high-income set-
tings, staying silent and keeping secrets about their experiences
of living with HIV in different social contexts (of which the
clinic or research study is one) is an important adolescent prac-
tice as both a protective and self-care strategy.79 How these
silences may operate in the context of children and adolescents
living with HIV in Kenya need to be further explored.
One of the most routinely reported outcomes by both chil-
dren and caregivers related to HIV stigma was experiencing
anxiety, stress, depression, and a negative outlook for the
future. This is consistent with other studies that showed that
HIV stigma is associated with increased risks for mental health
issues in adults80–82 and adolescents.83,84 Stigma items related
to experiencing anxiety, depression, and negative outlook
showed high construct validity with the SDQ, an instrument
designed to measure emotional and behavioral symptoms. Sur-
prisingly, no child or caregiver stigma items showed significant
Table 3. Association of Stigma Questionnaire Items with Relevant
Constructs.a
Stigma Items
Association with Criterion Constructs
MEMS
Adherence SDQ
GHAC
General
Health
Viral
Load
Child stigma items
Q3a þ
Q4b þ
Q5a þ
Q5b þ
Q9 þ
Caregiver stigma items
Q1 þ
Q3 þ
Q4f 
Q5a þ
Q5b 
Q6b þ 
Q8 þ
Q9 
Q11a 
Q11e 
Q12c 
Q13 þ
Abbreviations: GHAC, General Health Assessment for Children; MEMS,
Medication Event Monitoring Systems; PHQ-9, Patient Health Questionnaire–9
item; SDQ, 25-item Strengths and Difficulties Questionnaire.
a+ indicates direction of the slope for stigma items significantly associated with
construct (P < .05). No stigma items were significantly associated with child- or
caregiver-reported adherence using the CAMP Adherence Questionnaire or
depression using the PHQ-9 questionnaire. Several stigma items were
associated with the GHAC but only within the General Health subdomain (ie,
no significant association with the other domains—physical functioning,
psychological functioning, social and role, HIV, and health care).
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construct validity with the PHQ-9, a common depression
screening instrument. Anecdotal evidence from the research
team in Kenya that administered the questionnaires to children
and their caregivers reported in debrief meetings their particu-
lar dissatisfaction with the PHQ-9 instrument and that partici-
pants were more likely to have difficulty understanding and
responding to these items during study assessments.
The finding that caregiver stigma items showed high con-
struct validity by the GHAC General Health domain but not
child stigma items is interesting. The GHAC General Health
domain asks about the child’s overall health, physical health,
emotional health, and daily activities on a 10-point scale from
very worst to very best. This finding may also be related to
children’s unwillingness to disclose physical and mental prob-
lems related to their HIV status or to the lack of sensitivity of
the particular measure. We did not find strong construct valid-
ity on stigma items by adherence to treatment in this study.
Quantitative adherence monitoring using the gold standard of
electronic dose monitoring (MEMS) revealed significant levels
of missed doses (eg, only 28% of children achieved >90%
doses taken during follow-up). Interesting, a study among Thai
youths living with HIV found while stigma reported using the
HIV Stigma Scale was not associated with adherence by quan-
titative assessment (visual analog scale), stigma was associated
with poorer adherence and missed doses by qualitative assess-
ment (in-depth interviews).85 In qualitative work in this setting,
we have also documented a strong association between HIV
stigma and child adherence to HIV medication.
There are a number of important limitations of this study to
consider. First, as noted earlier, one major difficulty of validat-
ing HIV stigma by its connection to mental and behavioral
health outcomes is the lack of validated instruments for chil-
dren and adolescents in sub-Saharan Africa.86 We could not
find any research that rigorously evaluated the validity of the
PHQ-9 in East Africa among children or adolescents, although
the PHQ-9 was evaluated among adults living with HIV
in western Kenya and showed good validity and reliability in
assessing Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition (DSM-IV) depressive disorders.87 A study in
Zambia found high rates of emotional problems among adoles-
cents living with HIV,88 but a study evaluating the validity of
the SDQ among HIV orphaned children in South Africa
showed valid clinical cutoffs for caregivers but not for chil-
dren.89 Second, while both the SDQ and PHQ-9 have been
translated into more than 60 languages, validation of the instru-
ments into many languages (eg, Kiswahili) has not been inves-
tigated.90 This validation study was tested in only one country
in sub-Saharan Africa, and there may be additional language
and cultural content challenges if using it in another setting.
Nonetheless, the Academic Model Providing Access to Health-
care program in Kenya is clinically representative of many in
sub-Saharan Africa,91,92 and the study sites included urban,
peri-urban, and rural clinical sites. Moreover, while partici-
pants had the choice to have the questionnaire administered
in English or Kiswahili, almost all participants chose Kiswa-
hili, which prevented us from comparing the validity of the
questionnaire when it was administered in English versus Kis-
wahili. Additional work adapting and retesting this stigma
instrument is ongoing. Third, enrollment in this study was done
via convenience sampling. It is possible that children or their
caregivers who were experiencing higher levels of HIV stigma
would have been less inclined to enroll in the study, which
required participation in study assessments and keeping med-
ication in MEMS bottles. Additionally, the instrument was only
tested in disclosed children, as the questionnaire directly asks
about HIV. Finally, the stigma instrument was delivered by 8
research assistants (1 per clinic). To improve standardization of
instrument administration, extensive training sessions and
bimonthly meetings with the senior research team to discuss
study assessments were conducted.
Conclusion
We provide evidence for the reliability and validity of a cultu-
rally tailored and patient-informed instrument to measure HIV-
related stigma among Kenyan children and families. The
stigma instrument showed good reliability and construct valid-
ity was high on child- and caregiver-reported emotional and
behavioral health, with higher levels of reported HIV stigma
associated with poorer mental health. While additional testing
of this instrument is required, our study provides an important
contribution to the limited literature on instruments to measure
Table 4. Agreement Between Child- and Caregiver-Reported Individual Stigma Items.
Stigma Item
Month 18 Month 24
k P Value % Agreement k P Value % Agreement
Child lost friends due to HIV .03 .7670 85.7 .03 .6098 90.2
Child called names/bullied/insulted due to HIV .09 .2857 84.0 .13 .0488 87.4
Child experienced discrimination at home due to HIV .34 <.0001 92.4 .18 .0190 90.7
Child experienced discrimination in neighborhood due to HIV .05 .5546 87.9 .11 .0825 92.0
Child experienced discrimination at church due to HIV 0 n/a 99.2 .01 .8860 97.3
Child experienced discrimination at clinic due to HIV n/a n/a 100 0 n/a 98.0
Child experienced discrimination at school due to HIV 0.39 <.0001 92.9 0.53 <.0001 96.0
Child experienced discrimination at another place due to HIV 0 n/a 99.2 0 n/a 97.8
n/a: Not applicable.
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